Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-Valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2013
At a glance
- Drugs Valrubicin (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- 19 Sep 2005 New trial record.